Optimal mCRPC Drug Sequences Emerging
Recent studies provide guidance on which drugs should be used first to obtain the best outcomes.
PROSTATE CANCER ADVISOR
Prostate Cancer
Features
-
-
Kegel Exercises After Prostate Surgery Called Into Question
Pelvic physical therapy may be more appropriate than Kegel exercises in managing post-radical prostatectomy pain and stress urinary incontinence, according to a new study. -
Novel Antiandrogens and Cognitive Function
The authors of a recent review say they believe only a fraction of the men on androgen receptor-directed therapies who experience cognitive impairment report it. -
Study Identifies Racial Differences in Prostate Cancer Gene Expression Tests
Commercially available gene expression tests for predicting prostate cancer progression appear to be less accurate in black vs white men, according to a new study. -
Multidisciplinary Prostate Cancer Clinics May Promote Optimal Care
Receiving prostate cancer care at multidisciplinary clinics facilitates adherence to evidence-based national guidelines and potentially ameliorates bias in treatments, a study found.
Latest Prostate Cancer News
Prostate Cancer Surgical Approach Not a Factor in Treatment Decision Regret
Type of surgical approach to radical prostatectomy—robot-assisted vs open procedure—is not associated with a patient’s intermediate-term decision regret, according to a recent study.
Patient-Reported Outcomes That May Affect Treatment Decisions in Prostate Cancer
Validated PROMs can assist in providing high-quality care and improve a patient’s overall experience.
Overall Survival in mCRPC Cases Linked to Number of Radium-223 Doses
Men with metastatic castration-resistant prostate cancer with predominantly bone metastases who receive more than 4 dose of radium-223 have significantly improved overall survival than those who receive 4 or fewer doses, a study found.
Earlier Cabazitaxel Use in mCRPC Possibly Beneficial
Phase 2 trial results suggests abiraterone used in combination in cabazitaxel in men with chemotherapy-naïve metastatic castration-resistant prostate cancer might prolong radiographic progression-free survival compared with abiraterone alone.
Longer Survival Seen With Sipuleucel-T Use in mCRPC
In a study of men with metastatic castration-resistant prostate cancer, sipuleucel-T immunotherapy used at any point during treatment was associated with a decreased risk of death compared with utilization of newer oral androgen pathway inhibitors therapy without sipuleucel-T.
Intermittent Enzalutamide Dosing for mCRPC Probed
In a small study, intermittent vs continuous dosing was associated with improved overall survival and prolonged time on treatment.
Cabazitaxel Linked to Better Pain Reduction in mCRPC
A new analysis of men in the CARD study showed that cabazitaxel improved pain response and decreased the likelihood of pain progression compared with either abiraterone or enzalutamide.
Prostate Cancer Death Risk Not Linked to 5-ARIs
Investigators found that men treated with 5-alpha-reductase inhibitors are not more likely to die from prostate cancer or any other cause.
Modest Survival Gains Reported in Newly Diagnosed Metastatic PCa
Despite the introduction in recent year of promising novel agents, men with newly diagnosed metastatic prostate cancer have experienced only a slight decline in death risk.
Imaging Needed to Identify Bone Metastases in Advanced PCa
Bone imaging cannot be safely omitted in advanced prostate cancer cases because no PSA level combined with T stage and Gleason Grade Group can accurately rule in bone metastases, a new study found.
Want to read more?
Please login or register first to view this content.
Next post in Prostate Cancer
